DCA (Dichloroacetate) infusion is a treatment used in some cancer patients based on its potential to target cancer cell metabolism. The therapy exploits the Warburg effect, a phenomenon where cancer cells rely heavily on glycolysis for energy, even in the presence of oxygen. DCA works by reactivating the mitochondria in cancer cells, encouraging them to shift back to normal cellular respiration (oxidative phosphorylation), which can potentially slow or stop tumor growth.

In cancer therapy, DCA is often used as an adjunct to conventional treatments such as chemotherapy, radiation, or immunotherapy, but it is not a standard treatment. It is mainly used in experimental settings or by patients seeking alternative options when other therapies have not been successful.

Key points:

• Mechanism: DCA inhibits the enzyme pyruvate dehydrogenase kinase (PDK), which leads to mitochondrial reactivation in cancer cells, promoting apoptosis (programmed cell death) and reducing tumor growth.
• Potential Benefits: May slow tumor progression, particularly in certain cancers like glioblastomas, lung, breast, and other solid tumors. Some small studies and case reports suggest DCA may have a positive effect on tumor shrinkage.
• Administration: DCA is administered intravenously or orally, often in cycles, and the dose is tailored to the patient’s condition and tolerance.
• Side Effects: The most common side effects include peripheral neuropathy (nerve damage), gastrointestinal discomfort, and liver function abnormalities. Neuropathy is dose-dependent and can sometimes be managed by adjusting the dosage.

DCA shows promise in preclinical and early clinical studies, but patients considering DCA should do so under the guidance of an oncologist and be part of clinical trials or receive careful medical supervision.